Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB623 for chronic motor deficit from TBI
NCT02416492Phase 2Completed
- Sponsor
- SanBio
- Start
- Jul 2016
- Primary completion
- Jan 2019
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of vandefitemcel in traumatic brain injury (TBI) (4 arms), sponsored by SanBio. Primary endpoint: Fugl-Meyer Motor Scale Score at 24 weeks. Started Jul 2016; status: completed.
02
Drugs
vandefitemcel
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02416492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02416492.